Skip to main content
$35.99 -$0.48 (-1.3%)

04:30 PM EDT on 09/24/20

Fate Therapeutics (NASDAQ:FATE)

CAPS Rating: 4 out of 5

Current Price $35.99 Mkt Cap $3.2B
Open $36.39 P/E Ratio 0.00
Prev. Close $36.47 Div. (Yield) $0.00 (0.0%)
Daily Range $35.51 - $37.17 Volume 285,893
52-Wk Range $12.59 - $39.45 Avg. Daily Vol. 820,222

Caps

How do you think NASDAQ:FATE will perform against the market?

Add Stock to CAPS Watchlist

All Players

43 Outperform
3 Underperform
 

All-Star Players

12 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:FATE Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:FATE VS S&P 500 (SPY)

NASDAQ:FATE Summary

Fools bullish on NASDAQ:FATE are also bullish on:

Fools bearish on NASDAQ:FATE are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about FATE.

Recs

0
Member Avatar odocoileus (54.49) Submitted: 2/2/2020 6:12:25 PM : Outperform Start Price: $20.02 NASDAQ:FATE Score: +84.20

I admit there was a bit of FOMO going on when I green-thumbed this stock. I think it was the big words that impressed me most. Pluri-potent stem cells. How can you not want to open your wallet and just start dishing it out? While my lack of DD is apparent, I can say that I'm impressed with a couple of things. One is the number of candidates FATE has in the pipeline. The other is that many of these candidates try to attack more than one weakness on a cancer cell. FT596 is a good example. The problem with attacking a single site is that the cell line has a tendency to work around that attack. You may have initial good results, but the surviving cells then produce more cells resistant to that drug. You can use combo therapy or a drug that targets more than one site on the cancer cell. FATE is doing both. I get excited when I see this and tend to green-thumb stuff before I really know enough to make an informed decision. Take that into consideration.

Recs

0
Member Avatar XMFBlacknGoldX (95.71) Submitted: 12/13/2019 10:22:08 AM : Outperform Start Price: $13.47 NASDAQ:FATE Score: +171.40

From 12/09/2019:

"In total, Fate Therapeutics has 13 different programs in various stages of development. Whether that means the company lacks focus or has many shots on goal, Wall Street appears to be waiting for more concrete evidence that any of its drug candidates actually work. Given the tumbling stock price and a market valuation of only $1 billion, the risk-reward presented by this small-cap biotech stock could turn a small position into a long-term stroke of genius for patient investors."

https://www.fool.com/investing/2019/12/09/2-top-biotech-stocks-to-buy-in-december.aspx

Recs

0
Member Avatar NoPlaceLikeHome (65.26) Submitted: 3/9/2017 10:28:18 AM : Outperform Start Price: $4.09 NASDAQ:FATE Score: +766.97

With a phase 3 trial that can support an FDA application for approval of Zilretta, a non-opioid therapy for knee pain in osteoarthritis patients, under their belt, they are on the road to final approval. Long story short, if it gets the FDA green light, 10% market penetration is over $1B in revenue. It is non-opiod which means prescribers and patients do not have to hassle with increased scrutiny writing and filling scripts and I believe that will make market penetration very easy. At under $200 million in market cap and a $1B+ opportunity, I can't pass up the risk/reward. Buy!!

Leaderboard

Find the members with the highest scoring picks in FATE.

Score Leader

stainsolution

stainsolution (71.61) Score: +2,190.73

The Score Leader is the player with the highest score across all their picks in FATE.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
stainsolution 71.61 2/17/2016 Outperform 5Y $1.57 +2,258.47% +67.74% +2,190.73 0 Comment
oscillation 74.56 2/11/2016 Outperform 5Y $1.72 +2,052.19% +77.15% +1,975.03 1 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. biznessdoc 64.22 8/15/2016 Outperform 5Y $2.57 +1,336.19% +47.79% +1,288.40 0 Comment
portefeuille2 99.32 8/17/2016 Outperform 5Y $2.65 +1,292.83% +48.39% +1,244.44 0 Comment
shonny2 41.42 2/6/2017 Outperform 5Y $2.87 +1,186.06% +41.35% +1,144.72 0 Comment
NoPlaceLikeHome 65.26 3/9/2017 Outperform 5Y $4.09 +803.55% +36.58% +766.97 3 Comments
Under5 27.51 11/16/2017 Outperform 5Y $4.40 +738.84% +25.03% +713.82 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. TruffelPig < 20 3/1/2017 Outperform 5Y $4.40 +738.86% +35.70% +703.16 0 Comment
skellsmother < 20 11/11/2013 Outperform 1Y $4.45 +729.44% +82.46% +646.98 1 Comment
cyberterrorist < 20 11/12/2013 Outperform 1Y $4.51 +718.40% +82.83% +635.57 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for FATE.